Reducing effect of matrix metalloproteinase inhibitors on serum triacylglycerol in streptozotocin-induced diabetic rats and zucker fa/fa rats

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 8, 2007, Pages 1461-1467

  Morikawa, Tadanori ^a   Toyama, Tomoaki ^b   Kudo, Naomi ^b   Kawashima, Yoichi ^b  

^a Daiichi Fine Chemical Co Ltd   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Matrix metalloproteinase inhibitor; Serum triacylglycerol; Streptozotocin induced diabetic rat; Wound healing; Zucker fa fa rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; F 61 1008; FATTY ACID; FYK 1352; FYK 1388; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE INHIBITOR; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IC 50; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER LEVEL; LIVER WEIGHT; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; WOUND HEALING; ZUCKER DIABETIC FATTY RAT;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; ANTILIPEMIC AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, NONESTERIFIED; GUANIDINES; HYDROXAMIC ACIDS; LIPIDS; MALE; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES; WOUND HEALING;

EID: 34548013792     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.1461     Document Type: Article

References (20)

1. Goodson W. H., Hunt T. K., J. Surg. Res., 22, 221-227 (1977).
2. Seifter E., Rettura G., Padawer J., Stratford F., Stanford F., Ann. Surg., 194, 42-50 (1981).
3. Hennessey P. J., Edward G. F., Thomas B. C., Andrassy R. J., J. Pediatr. Surg., 25, 75-78 (1990).
4. Tsurumi K., Hiramastu Y., Hyashi G., Fujimura H., Pharmacometrics, 7, 833-843 (1973).
5. Yamamoto M., Tsujishita H., Hori N., Ohishi Y., Inoue S., Ikeda S., Okada Y., J. Med. Chem., 41, 1209-1217 (1998).
6. Folch J., Lees M., Sloane-Stanley G. H., J. Biol. Chem., 226, 497-509 (1957).
7. Terada M., Mizuhashi F., Tomita T., Murata K., J. Toxicol. Sci., 23, 235-241 (1998).
8. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C., Circulation, 98, 2088-2093 (1998).
9. Hert J. R., Bishars-Sieban J., Bar-Tana J., J. Biol. Chem., 270, 13470-13475 (1995).
10. Peters J. M., Hennuyer N., Staels B., Fruchart J.-C., Fievet C., Gonzalez F. J., Auwerx J., J. Biol. Chem., 272, 27307-27312 (1997).
11. Aoyama T., Peters J. M., Iriotani N., Nakajima T., Furihata K., Hashimoto T., Gonzalez F. J., J. Biol. Chem., 273, 5678-5684 (1998).
12. Kamanna V. S., Kashyap M. L., Curr. Atheroscler. Report, 2, 36-46 (2000).
13. Nestel P. J., Connor W. E., Reardon M. F., Connor S., Wong S., Boston R., J. Clin. Invest., 74, 82-89 (1984).
14. Illingworth D. R., Harris W. S., Connor W. E., Arteriosclerosis, 4, 270-275 (1984).
15. Lottenberg A. M. P., Oliveira H. C. F., Nakandakare E. R., Quintao E. C. R., Lipids, 27, 326-330 (1992).
16. George S. J., Exp. Opin. Invest. Drugs, 9, 993-1007 (2000).
17. Loftus I. M., Naylor A. R., Bell P. R., Br. J. Surg., 89, 680-694 (2002).
18. Galis Z. S., Khatri J. J., Circ. Res., 90, 251-262 (2002).
19. Koh K. K., Ahn J. Y., Jin D. K., Han S. H., Kim S. H., Choi I. S., Ahn T. H., Shin E. K., Jeong E. M., Int. J. Cardiol., 97, 239-244 (2004).
20. Leu H. B., Chen J. W., Wu T. C., Ding Y. A., Lin S. J., Charng M. J., Clin. Cardiol., 28, 423-428 (2005).